Msd Sub Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and what generic alternatives to MSD SUB MERCK drugs are available?
MSD SUB MERCK has fourteen approved drugs.
There are twenty US patents protecting MSD SUB MERCK drugs.
There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for Msd Sub Merck
International Patents: | 549 |
US Patents: | 20 |
Tradenames: | 13 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | STEGLATRO | ertugliflozin | TABLET;ORAL | 209803-002 | Dec 19, 2017 | RX | Yes | Yes | 8,080,580 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-002 | Dec 19, 2017 | RX | Yes | No | 9,308,204 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Msd Sub Merck | STEGLUJAN | ertugliflozin; sitagliptin phosphate | TABLET;ORAL | 209805-001 | Dec 19, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-001 | Feb 2, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Msd Sub Merck | ZEPATIER | elbasvir; grazoprevir | TABLET;ORAL | 208261-001 | Jan 28, 2016 | RX | Yes | Yes | 7,973,040 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Sub Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | 7,169,780*PED | ⤷ Try a Trial |
Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | 7,265,099 | ⤷ Try a Trial |
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | 5,478,820*PED | ⤷ Try a Trial |
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-002 | Feb 2, 2012 | 6,890,898 | ⤷ Try a Trial |
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | 5,807,825 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Extended-release Tablets | 100 mg/1000 mg | ➤ Subscribe | 2012-10-22 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
➤ Subscribe | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2012-03-16 |
➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
International Patents for Msd Sub Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | E534645 | ⤷ Try a Trial |
Israel | 215094 | ⤷ Try a Trial |
South Africa | 201203486 | ⤷ Try a Trial |
Cuba | 24003 | ⤷ Try a Trial |
Georgia, Republic of | P20063848 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Sub Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2310095 | 300857 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE |
0863901 | PA2004008,C0863901 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEMUM ((4R,5S,6S)-3-((3S,5S)-5-((3-KARBOKSIFENIL)AMINO)KARBONIL)-3-PIROLIDINIL)TIO)-6-((1R)-1HIDROKSIETIL)-4-METIL-7-OKSO-1-AZABICIKLO-(3.2.0)HEPT-2-EN-2-KARBOKSIRUGSTIS; REGISTRATION NO/DATE: 03/8043/3 20030328 |
1441735 | 122008000016 | Germany | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES KALIUMSALZES; REGISTRATION NO/DATE: EU/1/07/436/001-002 20071220 |
1506211 | C300677 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
2310095 | LUC00002 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: GRAZOPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI / ZEPATIER - ELBASVIR/GRAZOPREVIR; AUTHORISATION NUMBER AND DATE: EU/1/16/1119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.